Search
Search Results
-
Plasma Biomarkers of Alzheimer’s Disease and Neurodegeneration According to Sociodemographic Characteristics and Chronic Health Conditions
Ultrasensitive assays have been developed which enable biomarkers of Alzheimer’s disease pathology and neurodegeneration to be measured in blood....
-
Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease
BackgroundEasily accessible and self-administered cognitive assessments that can aid early detection for Alzheimer’s disease (AD) dementia risk are...
-
Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients
In this commentary, we address a paper published by Johnson et al. by assessing the robustness of their method to discover diagnostic biomarkers in...
-
Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer’s Disease Continuum
In the past years, neuroinflammation has been widely investigated in Alzheimer’s disease (AD). Evidence from animal, in vivo and post-mortem studies...
-
Associations of liver function with plasma biomarkers for Alzheimer’s Disease
BackgroundBlood-based biomarkers for Alzheimer’s disease (AD) are promising to be used in clinical settings. The liver is an important degradation...
-
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease
Changes in biomarker levels of Alzheimer’s disease (AD) reflect underlying pathophysiological changes in the brain and can provide evidence of direct...
-
Plasma biomarkers for prediction of Alzheimer’s disease neuropathologic change
While plasma biomarkers for Alzheimer’s disease (AD) are increasingly being evaluated for clinical diagnosis and prognosis, few population-based...
-
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy
BackgroundRecently, two monoclonal antibodies that lower amyloid plaques have shown promising results for the treatment of Mild Cognitive Impairment...
-
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer’s Disease. Are We Ready for the New Era?
Recent positive trials for novel disease modifying therapies of anti-amyloid monoclonal antibodies represent a paradigm shift in the prevention and...
-
Correlation between serum biomarkers, brain volume, and retinal neuronal loss in early-onset Alzheimer’s disease
PurposeTo compare the peripapillary retinal nerve fiber layer (pRNFL), retinal nerve fiber layer (RNFL), and ganglion cell complex (GCC) thickness...
-
Potential Ocular Biomarkers for Early Detection of Alzheimer’s Disease and Their Roles in Artificial Intelligence Studies
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Early detection is believed to be essential to disease management because it...
-
Bile acid profile associated with CSF and PET biomarkers in Alzheimer’s disease
BackgroundRecent studies have shown that gut microbiota can affect the development of Alzheimer’s disease (AD) through various mechanisms. Bile acids...
-
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer’s Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions
BackgroundCardiovascular risk factors are associated with Alzheimer’s Disease (AD) development. However, few studies compare the overall...
-
Multiomics Blood-Based Biomarkers Predict Alzheimer’s Predementia with High Specificity in a Multicentric Cohort Study
BackgroundThe primary criteria for diagnosing mild cognitive impairment (MCI) due to Alzheimer’s Disease (AD) or probable mild AD dementia rely...
-
Association between Longitudinal Cerebrospinal Fluid Alzheimer’s Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer’s Dementia Cohort Study (EPAD LCS)
BackgroundIn the absence of preventative pharmacological interventions for Alzheimer’s Disease dementia, there is a growing interest in modifiable...
-
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer’s Disease: An Overview of Tests for Clinical Practice in the United States and Europe
Amyloid and tau biomarkers for Alzheimer’s disease are widely recognized diagnostic tools for the identification of Alzheimer’s disease pathology...
-
Integrated Bioinformatic Analysis and Validation Identifies Immune Microenvironment-Related Potential Biomarkers in Alzheimer’s Disease
BackgroundAlzheimer’s disease (AD) is one of the most common neurodegenerative diseases, accompanied by cognitive and memory impairment, accounting...
-
Monitoring synaptic pathology in Alzheimer’s disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives
Alzheimer’s disease (AD) is currently constrained by limited clinical treatment options. The initial pathophysiological event, which can be traced...
-
Posttraumatic stress symptom severity predicts cognitive decline beyond the effect of Alzheimer’s disease biomarkers in Veterans
Chronic stress is a risk factor for dementia but whether it explains unique variance in cognitive decline in older adults above Alzheimer’s disease...
-
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer’s Disease Trials
BackgroundAdvances in plasma biomarkers to detect Alzheimer’s disease (AD) biology allows researchers to improve the efficiency of participant...
